

miR-130a对胰腺癌细胞系PANC-1细胞增殖和凋亡的调控作用及其机制探讨

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年11期 页码: 1866-1871 栏目: 论著 (基础研究) 出版日期: 2019-04-30

Title: Regulation and mechanism of miR-130a on proliferation and apoptosis of pancreatic cancer cell line PANC-1

作者: 胡川; 段俊伟; 杨帆; 余昌文; 戴丹菁

汉川市人民医院肿瘤科, 湖北汉川 431600

Author(s): Hu Chuan; Duan Junwei; Yang Fan; Yu Changwen; Dai Danjing

Department of Oncology, Hanchuan People's Hospital, Hubei Hanchuan 431600, China.

关键词: miR-130a; FOS样抗原1; 胰腺癌细胞; 细胞增殖; 细胞凋亡

Keywords: miR-130a; FOS like antigen 1; pancreatic cancer cells; cell proliferation; cell apoptosis

分类号: R735.9

DOI: 10.3969/j.issn.1672-4992.2019.11.005

文献标识码: A

摘要: 目的: 研究miR-130a对胰腺癌细胞系PANC-1细胞增殖和凋亡的影响, 并探讨其机制。方法: 体外培养胰腺癌细胞PANC-1、SW 1990、MIA PaCa-2和正常胰腺上皮细胞HPDE6-C7, 检测各细胞中miR-130a表达水平。将PANC-1细胞分为miR-130a低表达组 (miR-130a-inhibitor组) 、阴性对照组 (miR-130a-NC组) 和空白对照组 (miR-130a-BC组) 。转染48 h后, CCK-8试验检测细胞增殖情况; 裸鼠皮下成瘤实验检测miR-130a对肿瘤体内生长的影响; 流式细胞术检测细胞凋亡情况; TargetScan数据库预测miR-130a的靶基因, 并采用蛋白免疫印迹 (WB) 和荧光素酶报告实验进行验证。结果: PANC-1、SW 1990、MIA PaCa-2人胰腺癌细胞中miR-130a表达水平平均显著高于正常胰腺上皮细胞, 差异有统计学意义 ($P<0.05$) 。转染miR-130a-inhibitor后, PANC-1细胞miR-130a相对表达量显著下调 ($P<0.05$) ; 与miR-130a-NC和miR-130a-BC组比较, miR-130a-inhibitor组PANC-1细胞增殖能力显著下降 ($P<0.05$) 、裸鼠皮下肿瘤体积明显减小 ($P<0.05$) 、细胞凋亡率显著升高 ($P<0.05$) 。TargetScan数据库显示FOS样抗原1 (FOSL1) 是miR-130a潜在靶基因, WB和双荧光素酶报告实验证实FOSL1是miR-130a的作用靶点。结论: 下调miR-130a表达通过作用于FOSL1基因抑制PANC-1细胞增殖, 促进其凋亡, 可能为胰腺癌的临床治疗提供新思路。

Abstract: Objective: To study the influences of miR-130a on the proliferation and apoptosis of pancreatic cancer cell line PANC-1 cell and to explore its mechanisms.Methods: Pancreatic cancer cells PANC-1, SW 1990, MIA PaCa-2 and normal pancreatic epithelial cell HPDE6-C7 were cultured in vitro.The expression of miR-130a in each cell was detected.PANC-1 cells were divided into miR-130a low expression group (miR-130a-inhibitor group), negative control group (miR-130a-NC group) and blank control group (miR-130a-BC group).After transfection for 48 h, CCK-8 assay was used to detect cell proliferation.The effect of miR-130a on the growth of tumor in vivo was detected by subcutaneous tumor formation experiment in nude mice.Cell apoptosis was detected by flow cytometry.The target genes of miR-130a were predicted by TargetScan database and verified by Western blot (WB) and luciferase assay.Results: The expression level of miR-130a in pancreatic cancer cells of PANC-1, SW 1990 and MIA PaCa-2 was significantly higher than that in normal pancreatic epithelial cells , and the difference was statistically significant ($P<0.05$).After transfection of miR-130a-inhibitor, the relative expression of miR-130a in PANC-1 cells was significantly reduced ($P<0.05$).Compared with miR-130a-NC group and miR-130a-BC group, the proliferation ability of PANC-1 cells in group miR-130a-inhibitor decreased significantly ($P<0.05$), the volume of subcutaneous tumor in nude mice decreased significantly ($P<0.05$), and the rate of apoptosis significantly increased ($P<0.05$).The TargetScan database showed that FOS like antigen 1 (FOSL1) was a potential target gene for miR-130a, WB and double luciferase reporter experiments confirmed that FOSL1 was the action target of miR-130a.Conclusion: Down-regulating the expression of miR-

130a can inhibit the proliferation and promote the apoptosis of PANC-1 cells by acting FOSL1 gene, may provide new ideas for the clinical treatment of pancreatic cancer.

参考文献/REFERENCES

- [1] Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer [J]. *Nature*, 2016, 531(7592): 47-52.
- [2] Llop E, E Guerrero P, Duran A, et al. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma [J]. *World J Gastroenterol*, 2018, 24(4): 2537-2554.
- [3] Swl DG, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review [J]. *Cancer*, 2017, 123(21): 4158-4167.
- [4] Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics [J]. *Theranostics*, 2014, 4(12): 1211-1232.
- [5] González-Quintana V, Palma-Berré L, Campos-Parra AD, et al. MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review) [J]. *Oncol Rep*, 2016, 35(1): 3-12.
- [6] Shen S, Guo X, Yan H, et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis [J]. *Cell Research*, 2015, 25(9): 997-1012.
- [7] Wu LM, Wu SG, Chen WW, et al. Construction of nude mouse models bearing subcutaneous tumors: Human osteosarcoma cell lines MG63, U2OS and 143B [J]. *Journal of Clinical Rehabilitative Tissue Engineering Research*, 2015, 81(27): 4277-4281. [吴丽美, 伍绍国, 陈卫文, 等. 构建裸鼠皮下荷瘤模型: 人骨肉瘤细胞株MG63、U2OS和143B [J]. 中国组织工程研究, 2015, 81(27): 4277-4281.]
- [8] Kang YA, Li NF, Hu YR, et al. Study on detection of expression of GIRK4 gene in renal tissue of SD rats by Western-blotting [J]. *Journal of Clinical and Experimental Medicine*, 2013, 12(4): 241-242. [康永安, 李南方, 胡燕荣, 等. 蛋白质印迹法检测GIRK4在SD大鼠肾脏组织的表达 [J]. 临床和实验医学杂志, 2013, 12(4): 241-242.]
- [9] Nair VB, Manasa VG, Sinto MS, et al. Differential expression of microRNAs in uterine cervical cancer and its implications in carcinogenesis: An integrative approach [J]. *Int J Gynecol Cancer*, 2018, 28(3): 553-562.
- [10] Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer [J]. *Nature Reviews Cancer*, 2015, 15(6): 321-333.
- [11] Mody H, Hung SW, Pathak R, et al. miR-202 diminishes TGFbeta receptors and attenuates TGFbeta1-induced EMT in pancreatic cancer [J]. *Mol Cancer Res*, 2017, 15(8): 1029-1039.
- [12] Zhu Y, Gu J, Li Y, et al. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes [J]. *Cancer Lett*, 2018, 412(3): 59-68.
- [13] Jiang H, Yu WW, Wang LL, et al. miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3 [J]. *Oncol Rep*, 2015, 34(3): 1153-1161.
- [14] Cappellosso R, Galasso M, Nicolè L, et al. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology [J]. *Cancer Cytopathol*, 2017, 125(8): 635-643.
- [15] Pan Y, Wang R, Zhang F, et al. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A [J]. *Int J Clin Exp Pathol*, 2015, 8(1): 384-393.
- [16] Hu Y, Li J, Li SY, et al. Expression level of FOSL2 protein in Uygur patients with type 2 diabetes mellitus in Xinjiang [J]. *China Journal of Modern Medicine*, 2016, 26(5): 26-30. [胡颖, 李军, 李思源, 等. FOS样抗原2蛋白表达在新疆维吾尔族2型糖尿病中的应用 [J]. 中国现代医学杂志, 2016, 26(5): 26-30.]
- [17] Chen X, Zhao M, Huang J, et al. MicroRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1 [J]. *J Cell Biochem*, 2018, 119(6): 4945-4956.
- [18] Vallejo A, Valencia K, Vicent S. All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS [J]. *Mol Cell Oncol*, 2017, 4(3): e1314239.
- [19] Vallejo A, Perurena N, Guruceaga E, et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer [J]. *Nat Commun*, 2017, 8(1): 14294-14305.
- [20] Elangovan IM, Vaz M, Tamatam CR, et al. FOSL1 promotes KRAS-induced lung cancer through amphiregulin and cell survival gene regulation [J]. *Am J Respir Cell Mol Biol*, 2017, 58(5): 625-635.

备注/Memo: -

更新日期/Last Update: 2019-04-30